- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
Patent holdings for IPC class A61K 40/11
Total number of patents in this class: 1807
10-year publication summary
|
0
|
2
|
6
|
25
|
83
|
110
|
54
|
47
|
874
|
42
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| The Trustees of the University of Pennsylvania | 4380 |
45 |
| The Regents of the University of California | 20324 |
44 |
| Memorial Sloan-Kettering Cancer Center | 1980 |
33 |
| Iovance Biotherapeutics, Inc. | 352 |
33 |
| Kite Pharma, Inc. | 424 |
30 |
| The Board of Trustees of the Leland Stanford Junior University | 6553 |
26 |
| Juno Therapeutics, Inc. | 463 |
24 |
| City of Hope | 1008 |
22 |
| Autolus Limited | 264 |
20 |
| Fred Hutchinson Cancer Center | 460 |
19 |
| Board of Regents, The University of Texas System | 5966 |
18 |
| Janssen Biotech, Inc. | 1597 |
18 |
| The General Hospital Corporation | 4800 |
17 |
| Dana-Farber Cancer Institute, Inc. | 2620 |
17 |
| H. Lee Moffitt Cancer Center and Research Institute, Inc. | 993 |
17 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2921 |
17 |
| Allogene Therapeutics, Inc. | 155 |
17 |
| Novartis AG | 10506 |
15 |
| Memorial Hospital for Cancer and Allied Diseases | 335 |
14 |
| Regeneron Pharmaceuticals, Inc. | 4458 |
13 |
| Other owners | 1348 |